A narrative review of the principal glucocorticoids employed in cancer.

Glucocorticoids Immune checkpoint inhibitors Oncology Palliative care Supportive care

Journal

Seminars in oncology
ISSN: 1532-8708
Titre abrégé: Semin Oncol
Pays: United States
ID NLM: 0420432

Informations de publication

Date de publication:
12 2022
Historique:
received: 12 09 2022
revised: 15 01 2023
accepted: 16 01 2023
pubmed: 4 2 2023
medline: 15 3 2023
entrez: 3 2 2023
Statut: ppublish

Résumé

Glucocorticoids (GCs) are a pharmacological class of drugs widely used in oncology in both supportive and palliative settings. GCs differentially impact organs with immediate and long-term effects; with suppressive effect on the immune system anchoring their use to manage the toxicities of immune checkpoint inhibitors (ICIs). In addition, GCs are often used in the management of symptoms related to cancer or chemotherapy and as adjuvants in the treatment of pain in the management of other. In the palliative setting, GCs, especially administered subcutaneously can be to assist in the control of nausea, dyspnea, asthenia, and anorexia-cachexia syndrome. In this narrative review, we aim to summarize the role of GCs in the different settings (curative, supportive, and palliative) to help clinicians use these important drugs in their daily clinical practice with cancer patients.

Identifiants

pubmed: 36737303
pii: S0093-7754(23)00004-0
doi: 10.1053/j.seminoncol.2023.01.004
pii:
doi:

Substances chimiques

Glucocorticoids 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

429-438

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest B.P. was supported by ESMO with a Clinical Translational Fellowship aid supported by Roche. M.S. acted as consultant for MSD, BMS, Astra-Zeneca, Mercks, Amgen and Servier and received speaker honoraria from MSD, Mercks, Amgen ans Servier. A.M. received research grants from Roche and honoraria from Lilly, Novartis, EISAI, Seagen, Daiichi-Sankyo.

Auteurs

Nerina Denaro (N)

Medical Oncology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Ornella Garrone (O)

Medical Oncology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Annamaria Morelli (A)

SC Oncologia Collegno-Pinerolo, Italy.

Benedetta Pellegrino (B)

Medical Oncology and Breast Unit, University Hospital of Parma, Italy; Department of Medicine and Surgery, University of Parma, Italy.

Marco Carlo Merlano (MC)

Medical Oncology, IRCC Candiolo Cancer Institute, Candiolo (Turin), Italy.

Denise Vacca (D)

Palliative Care Unit, Ospedale Sirai, Carbonia, ASSL Carbonia, Italy.

Josie Pearce (J)

Harvard Premedical Program, Harvard University, Cambridge, MA, USA.

Daniele Farci (D)

Medical Oncology, Nuova Casa di Cura, Decimomannu, Cagliari, Italy.

Antonino Musolino (A)

Medical Oncology and Breast Unit, University Hospital of Parma, Italy; Department of Medicine and Surgery, University of Parma, Italy.

Mario Scartozzi (M)

Medical Oncology, AOU Cagliari, Policlinico di Monserrato, Cagliari, Italy.

Chiara Tommasi (C)

Medical Oncology and Breast Unit, University Hospital of Parma, Italy; Department of Medicine and Surgery, University of Parma, Italy. Electronic address: chiara.tommasi@unipr.it.

Cinzia Solinas (C)

Medical Oncology, AOU Cagliari, Policlinico di Monserrato, Cagliari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH